TRACER PHARMA ApS: Financial statements 2025
CVR: 34090106
Source: annual report 2025, Danish Business Authority
01/05/2024 – 30/04/2025
TRACER PHARMA ApS (CVR 34090106) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 5,203,816 and a net result of DKK 687,871 compared with DKK 1,705,344 the year before. That is a decrease of 3.9% compared with the year before. Equity in the 2025 report amounted to DKK 867,174. The solvency ratio was 38.2%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 5,203,816
- Profit/Loss
- DKK 687,871
- Equity
- DKK 867,174
- Total Assets
- DKK 2,271,524
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 5.2 mio. | 688 t. | 867 t. | 3 |
| 2024 | - | 5.4 mio. | 1.7 mio. | 2.1 mio. | 3 |
| 2023 | - | 4.1 mio. | 97 t. | 1.4 mio. | 5 |
| 2022 | - | 3.9 mio. | 145 t. | 1.6 mio. | 5 |
| 2021 | - | 4 mio. | 832 t. | 1.5 mio. | 5 |
Official annual report
How creditworthy is TRACER PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of November 28, 2025, Enver Edwin Medjedovic Hansen has stepped down as liquidator of TRACER PHARMA ApS.
On November 28, 2025, TRACER PHARMA ApS exited liquidation.
TRACER PHARMA ApS was dissolved on November 28, 2025.
As of April 1, 2025, Enver Edwin Medjedovic Hansen is registered as liquidator of TRACER PHARMA ApS.
As of April 1, 2025, Morten Hagelsten Jacobsen has stepped down as adm. dir. of TRACER PHARMA ApS.
On April 1, 2025, TRACER PHARMA ApS entered liquidation.
About TRACER PHARMA ApS
TRACER PHARMA ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2011. The company has been dissolved on 28 November 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 5,203,816 and a net result of DKK 687,871 compared with DKK 1,705,344 the year before. Equity in the 2025 report amounted to DKK 867,174.